These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 14571743

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab.
    Hassan C, Ierardi E, Burattini O, De Francesco V, Zullo A, Stoppino G, Panella C, Morini S.
    Dig Liver Dis; 2007 Sep; 39(9):811-7. PubMed ID: 17652038
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
    Dignass AU, Bokemeyer B, Adamek H, Mross M, Vinter-Jensen L, Börner N, Silvennoinen J, Tan G, Pool MO, Stijnen T, Dietel P, Klugmann T, Vermeire S, Bhatt A, Veerman H.
    Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis.
    Eliakim R, Tulassay Z, Kupcinskas L, Adamonis K, Pokrotnieks J, Bar-Meir S, Lavy A, Mueller R, Greinwald R, Chermesh I, Gross V, International Salofalk Foam Study Group.
    Aliment Pharmacol Ther; 2007 Nov 01; 26(9):1237-49. PubMed ID: 17944738
    [Abstract] [Full Text] [Related]

  • 10. Mucosal features and granulocyte-monocyte-apheresis in steroid-dependent/refractory ulcerative colitis.
    D'Ovidio V, Aratari A, Viscido A, Marcheggiano A, Papi C, Capurso L, Caprilli R.
    Dig Liver Dis; 2006 Jun 01; 38(6):389-94. PubMed ID: 16569521
    [Abstract] [Full Text] [Related]

  • 11. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan.
    Hibi T, Sameshima Y, Sekiguchi Y, Hisatome Y, Maruyama F, Moriwaki K, Shima C, Saniabadi AR, Matsumoto T.
    Dig Liver Dis; 2009 Aug 01; 41(8):570-7. PubMed ID: 19211314
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and tolerability of olsalazine (dipentum) in the treatment of patients with ulcerative colitis--results of a field study.
    Singer MV, Schmausser H, Schönfeld G.
    Hepatogastroenterology; 2006 Aug 01; 53(69):317-21. PubMed ID: 16795963
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
    Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, Lees K, Joseph RE, Sandborn WJ.
    Clin Gastroenterol Hepatol; 2007 Jan 01; 5(1):95-102. PubMed ID: 17234558
    [Abstract] [Full Text] [Related]

  • 16. The effect of acute psychologic stress on systemic and rectal mucosal measures of inflammation in ulcerative colitis.
    Mawdsley JE, Macey MG, Feakins RM, Langmead L, Rampton DS.
    Gastroenterology; 2006 Aug 01; 131(2):410-9. PubMed ID: 16890594
    [Abstract] [Full Text] [Related]

  • 17. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith-Hall N, Ajayi F.
    Am J Gastroenterol; 2005 Nov 01; 100(11):2478-85. PubMed ID: 16279903
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II.
    Riccioni C, Sarcinella R, Palermo G, Izzo A, Liguori M, Koverech A, Messano M, Virmani A.
    Int Angiol; 2008 Jun 01; 27(3):253-9. PubMed ID: 18506129
    [Abstract] [Full Text] [Related]

  • 20. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
    D'Haens G, Hommes D, Engels L, Baert F, van der Waaij L, Connor P, Ramage J, Dewit O, Palmen M, Stephenson D, Joseph R.
    Aliment Pharmacol Ther; 2006 Oct 01; 24(7):1087-97. PubMed ID: 16984503
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.